This Week in CRC Research

RESEARCH

Gut bacteria engineered to convert cholesterol into a tumor-suppressing metabolite show promise in preclinical colorectal cancer models — Nature: Colorectal Cancer

Researchers identified a cholesterol metabolite called 4-cholesten-3-one (4-C-3) that is depleted in colorectal cancer and can suppress tumor growth by blocking EGFR (epidermal growth factor receptor) activation and stabilizing mutant KRAS in an inactive state. In preclinical models, restoring 4-C-3 using either a naturally occurring gut bacterium or an engineered non-pathogenic Escherichia coli lowered intratumoral cholesterol and induced tumor regression without overt toxicity. The approach overcame KRAS-driven resistance to anti-EGFR therapy in laboratory models.

What this means

This preclinical work suggests a novel route to target colorectal cancer through the gut microbiome, particularly for tumors carrying KRAS mutations that typically resist standard therapies. Whether microbiome engineering can be translated safely and effectively into clinical practice remains an open question.

RESEARCH

Silencing DNA repair genes with nanoparticles restores immune response in microsatellite-stable colorectal cancer — Molecular Cancer

Microsatellite-stable (MSS) colorectal cancer, which represents the majority of cases, typically does not respond to immunotherapy because it has a low tumor mutational burden. Researchers developed lipid nanoparticles carrying small interfering RNA (siRNA) that silence key mismatch repair genes (MLH1, MSH2, and MSH6), achieving over 70% gene silencing in mouse models of MSS colorectal cancer. When combined with oxaliplatin chemotherapy, this approach substantially increased tumor mutational burden, expanded the repertoire of tumor-derived neoantigens, and promoted CD8+ T cell infiltration and activation. This combinatorial regimen effectively inhibited tumor progression in pMMR/MSS CRC across both subcutaneous and liver metastasis mouse models.

What this means

This preclinical strategy offers a potential path to make the majority of colorectal cancers, those that are microsatellite-stable, responsive to immunotherapy by artificially increasing their mutational burden. The approach remains investigational and has not yet been tested in human trials.

TRIAL DATA

Phase III trial shows survival benefit for tyrosine kinase inhibitor plus immunotherapy in pretreated microsatellite-stable colorectal cancer — ESMO Gastrointestinal Oncology

The interim analysis of the phase III STELLAR-303 trial demonstrated an overall survival benefit with the combination of zanzalintinib (a tyrosine kinase inhibitor, or TKI) plus atezolizumab (an immune checkpoint inhibitor) compared with regorafenib in pretreated microsatellite-stable colorectal cancer. Tyrosine kinase inhibitors can induce immunological reprogramming of the tumor microenvironment, promoting proinflammatory macrophage polarization, antigen presentation, vascular normalization, and T-cell infiltration, which may help overcome the intrinsic resistance of MSS tumors to immunotherapy.

What this means

This is the first phase III trial to show a survival advantage for combining a tyrosine kinase inhibitor with immunotherapy in microsatellite-stable colorectal cancer, a population that has historically not benefited from immunotherapy alone. The role of liver metastases in modulating response remains an area of active investigation.

SCREENING

Positive stool DNA test still yields advanced neoplasia in one in five patients with a prior normal colonoscopy — Clinical and Translational Gastroenterology

A registry-based analysis from the New Hampshire Colonoscopy Registry compared colonoscopy outcomes after positive multitarget stool DNA (mt-sDNA) tests in 739 patients with a prior normal colonoscopy and 994 patients without a prior colonoscopy. Patients with a prior normal colonoscopy were approximately half as likely to have more advanced findings (odds ratio 0.51; 95% CI 0.41–0.62; P < 0.001), but the absolute prevalence of advanced colorectal neoplasia among patients with a previous colonoscopy remained substantial at 19.1% (95% CI 16.3–22.1%).

What this means

Even after a recent normal colonoscopy, a positive stool DNA test warrants follow-up colonoscopy, as nearly one in five such patients still harbor advanced neoplasia. Potentially reflecting lesions missed on the prior exam or rapid interval growth.

🔬 Under 50 Spotlight

Research relevant to early-onset and younger CRC patients

Risk factor profiles may differ between younger-onset and late-onset colorectal cancer. An exploratory analysis of the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial dataset (approximately 155,000 US participants including 1,219 CRC cases) stratified participants by age (≤59 vs. ≥60 years). Among the ≤59-year cohort, no individual risk factor (excluding age) was independently associated with the risk of CRC, whereas in the ≥60-year cohort, individual factors (sex, body mass index, diabetes, and alcohol) as well as combinations of risk factors were associated with CRC. Significant dietary patterns appeared exclusively to impact the risk of CRC in the ≥60-year cohort. These exploratory findings suggest that the drivers of CRC in younger individuals may be different from their older counterparts. Asia-Pacific Journal of Clinical Oncology

💙 Living with CRC

Survivorship, quality of life, and supportive care

Dietary guidance remains the most pressing unmet need among Chinese colorectal cancer survivors. A mixed-methods study of 216 Chinese CRC survivors found that unmet needs were most prominent in the health system and information domain, followed by psychological, patient care and support, physical and daily living, and sexuality domains. Qualitative findings highlighted persistent dietary information gaps, emotional concealment, and long chemotherapy waiting times. Mobile apps and printed materials were preferred for sexuality needs, whereas face-to-face consultations and mobile apps were preferred across other domains. Female sex and advanced stage were associated with higher psychological and physical/daily living needs; living with a colostomy markedly increased odds of sexuality needs. Psycho-Oncology

🔎 Screening Watch

Screening guidelines, early detection, and prevention advances

Liquid biopsy platforms show high diagnostic accuracy for colorectal cancer detection. A systematic review and meta-analysis of 43 studies evaluating liquid biopsy-based molecular diagnostics (qPCR, ddPCR, and NGS) for colorectal cancer found pooled sensitivity of 75% (95% CI, 0.70–0.79) and specificity of 91% (95% CI, 0.89–0.92). In subgroup analyses, NGS demonstrated a higher diagnostic odds ratio of 80.51 (95% CI, 26.13–248.08) and an AUC of 0.937. Mutation-based biomarkers showed a diagnostic odds ratio of 45.78 (95% CI, 17.79–117.8) with an AUC of 0.944, while plasma samples had a diagnostic odds ratio of 32.19 (95% CI, 21.02–49.29) and an AUC of 0.912. The findings suggest that plasma-based mutation analysis using NGS exhibits promising diagnostic accuracy for CRC, though further validation is required to confirm clinical utility. Journal of Biological Engineering

🧬 Biomarker Spotlight

Research by genetic subtype. KRAS, BRAF, MSI-H, HER2, and more

Compact plasma sequencing detects KRAS variants outside standard tissue assay targets. A prospective study of 39 patients with newly diagnosed unresectable metastatic colorectal cancer receiving first-line therapy used a 10 kb, 10-gene hybrid-capture sequencing panel with molecular barcodes and error correction to analyze cell-free DNA collected before treatment and after two and four cycles. Baseline oncogenic variants were detected in 32 of 35 evaluable patients (91.4%). Compared with routine tissue PCR for shared RAS/BRAF targets, plasma testing showed 84.2% sensitivity (16/19) and 100% specificity (19/19) in the intention-to-test cohort. Three activating KRAS variants (L19F, A59T, and A146T) lay outside the tissue assays' target regions; patients carrying these alterations received anti-EGFR therapy. International Journal of Molecular Sciences

HER2-directed antibody-drug conjugate shows limited activity in two patients with HER2-low colorectal cancer. Two case reports described patients with advanced CRC whose tumors were reported as HER2-positive by immunohistochemistry (IHC) score 2+ but were not confirmed by in situ hybridization (ISH)/fluorescence in situ hybridization (FISH) before treatment with trastuzumab rezetecan (SHR-A1811), a novel HER2-directed antibody-drug conjugate. Neither patient achieved an objective response (one progressive disease, one stable disease). Confirmatory testing showed the progressing lesion in Case 1 to be HER2-negative (IHC 0) and Case 2 to be FISH-negative (HER2-low). Journal of Gastrointestinal Oncology

Clinical Trials Update

Covered in this week's findings: STELLAR-303 phase III trial showing overall survival benefit for zanzalintinib plus atezolizumab versus regorafenib in pretreated microsatellite-stable colorectal cancer.

By the Numbers

19.1%

The prevalence of advanced colorectal neoplasia among patients with a prior normal colonoscopy who subsequently tested positive on a multitarget stool DNA test, according to a registry-based analysis from the New Hampshire Colonoscopy Registry. This finding underscores that a positive stool DNA test warrants follow-up colonoscopy even in patients who recently had a normal exam, potentially reflecting lesions missed on the prior colonoscopy or rapid interval growth.

Resources

No patient resource reported this week in the sources read.

Questions this raises for a care team

  • For microsatellite-stable colorectal cancer with liver metastases, whether the presence of hepatic disease modulates response to tyrosine kinase inhibitor plus immunotherapy combinations, and whether this should inform treatment sequencing, remains an open question.
  • For tumors carrying KRAS variants outside the target regions of standard tissue PCR assays (such as L19F, A59T, and A146T), whether plasma-based sequencing should be routinely incorporated to guide anti-EGFR therapy decisions is an area requiring further validation.
  • For patients with a positive multitarget stool DNA test following a recent normal colonoscopy, whether the nearly 20% prevalence of advanced neoplasia reflects primarily missed lesions versus rapid interval growth, and what this implies for colonoscopy quality benchmarks, is a question for further investigation.